glp 1 drugs kidney disease Potential kidney-protective and other effects of GLP-1 receptor Design and discovery of a
Description
Tirzepatide delivers stronger results but costs more
Across the market, competitive advantage is increasingly shaped by ease of self-administration, supply chain resilience, device reliability, and integrated patient-support ecosystems that sustain long-term treatment adherence in home-based obesity care
FUNDING This work was supported by the National Natural Science Foundation of China (82300903), the Key R&D Plan Social Development Project of Jiangsu Province (SBE2023741128), the National Natural Science Foundationof Jiangsu Province (SBK20 23022865), the sixth phase 333 second level talent training project of Jiangsu Province (tackling bottleneck technology) (BRA2022008), the Projects from Social Development of Zhenjiang (SH2023029), the Youth Science and Technology Talent Recruitment Project of Zhenjiang city (ZJTJ2101), the Affiliated Hospital of Jiangsu University Beigu Talent Cultivation Plan Project (BGYCB202206), the Affiliated Hospital of Jiangsu University Doctoral Initiation Fund Project (jdfykc2021005)
GLP-1RAs have been shown to exert a protective factor by reducing stroke (RR 0.84
In the Wegovy-pill clinical trial, 18% of people who received the medication discontinued the treatment, which was less than the 26% rate in the placebo group
Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, et al
